These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38155795)

  • 21. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation.
    Kaneko H; Yano Y; Itoh H; Morita K; Kiriyama H; Kamon T; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Carey RM; Lima JAC; Oparil S; Yasunaga H; Komuro I
    Circulation; 2021 Jun; 143(23):2244-2253. PubMed ID: 33886370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes.
    Mantovani A; Csermely A; Taverna A; Cappelli D; Benfari G; Bonapace S; Byrne CD; Targher G
    Diabetes Metab; 2023 Mar; 49(2):101416. PubMed ID: 36586476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults.
    Ha J; Hong OK; Han K; Kwon HS
    Diabetes Res Clin Pract; 2024 Jun; 212():111584. PubMed ID: 38367650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke.
    Chen S; Xue H; Huang R; Chen K; Zhang H; Chen X
    Diabetes Metab; 2023 Sep; 49(5):101468. PubMed ID: 37586479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
    Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
    Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
    Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction.
    Lee SB; Jin MH; Yoon JH
    Sci Rep; 2024 Mar; 14(1):6714. PubMed ID: 38509247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
    Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia.
    Vaz K; Kemp W; Majeed A; Lubel J; Magliano DJ; Glenister KM; Bourke L; Simmons D; Roberts SK
    Hepatol Int; 2024 Aug; 18(4):1135-1143. PubMed ID: 39008030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.